Photo credit: www.sciencedaily.com
Innovative Light-Activated Therapy for Aggressive Breast Cancer
A research collaboration between a husband-and-wife professor duo at Michigan State University (MSU) and scientists from the University of California, Riverside aims to revolutionize treatments for aggressive breast cancer through the development of a novel light-activated therapy.
Sophia Lunt, an expert in biochemistry and molecular biology, and Richard Lunt, a specialist in chemical engineering, are working alongside Vincent Lavallo, a chemistry professor at UC Riverside. Together, they are focusing on creating new light-sensitive compounds known as cyanine-carborane salts, which are integral to photodynamic therapy (PDT) that targets metastatic breast cancer tumors in mouse models while minimizing side effects.
“Our innovative cyanine-carborane salts offer a targeted option with reduced side effects for patients with aggressive breast cancer,” remarked Sophia Lunt. “We hope that this research will pave the way for safer and more effective therapies for individuals facing limited treatment choices.”
In the PDT process, these light-sensitive compounds circulate through the body and accumulate in cancer cells. When subjected to near-infrared light, which can penetrate tissue without being visible, these compounds become activated and function like a “smart” bomb, selectively destroying cancer cells while preserving healthy tissue.
“Current FDA-approved PDT chemicals tend to linger in other body areas, such as the skin, for extended durations,” stated Hyllana Medeiros, a postdoctoral researcher at MSU involved in the mouse studies. “Consequently, patients who undergo traditional PDT must avoid light exposure for two to three months to prevent their skin from blistering or burning due to even low light levels.”
The cyanine-carborane salts being developed showcase a superiority over conventional PDT agents, as they are effectively absorbed by cancer cells, leading to a more potent therapeutic effect.
“Our findings contribute significantly to treating aggressive breast cancers,” explained Amir Roshanzadeh, a graduate student at MSU and the lead author of the published research. “Moreover, this work lays the groundwork for potential breakthroughs in addressing other cancer types and advancing targeted drug delivery methods.”
Looking ahead, the research team intends to evaluate the effectiveness of these innovative salts against various cancer forms.
“Tackling complexities like cancer demands the collaboration of multidisciplinary teams like ours,” remarked Richard Lunt. “This research exemplifies the remarkable outcomes that can arise when experts from diverse fields—ranging from cancer biology to chemistry and materials science—come together to address significant health challenges.”
Source
www.sciencedaily.com